Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Artichoke Extract wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
8 of 9 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Artichoke Extract and Semaglutide have evidence — compare verdict strength side-by-side.
600-1200mg extract daily
Before meals (especially fatty meals), Divided doses
Standardized leaf extract (2.5-5% cynarin)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
2-4 weeks
8-12 weeks
4-8 weeks
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis
Critical reviews in food science and nutrition (2018) · Meta analysis · n=702
Quantitative data synthesis was performed using a random-effects model, with weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics.
Functional and Therapeutic Potential of Cynara scolymus in Health Benefits
Nutrients (2024) · Systematic review
This reduces the subsequent risk of developing conditions such as cancer, diabetes, and cardiovascular diseases.
The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature. Part II
Phytotherapy research : PTR (2024) · Systematic review
The available evidence showed promising hypoglycemic effects of the nutraceuticals reviewed both for their efficacy and safety profile.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Based on meta-analysis of 702 subjects showing 17.6 mg/dL reduction in total cholesterol. Effect size is modest and may require 6+ weeks to manifest. Limited to artichoke leaf extract studies.
AI-estimated from published studies. Interpret as directional guidance.
Artichoke Extract has a higher evidence score (7/10 vs 8.5/10) and wins in 2 of 3 categories.
No known interactions between Artichoke Extract and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.